Revolution Medicines Inc - Warrants (17/12/2026)
RVMDW
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.77B
Close$
$1.18
85.9% downside
Current Fair Value
85.9% downsideOvervalued by 85.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.77 Billion |
|---|---|
| Enterprise Value | $1.60 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.95 |
| Beta | 1.4 |
| Outstanding Shares | 210,893,604 |
Return
| Return on Equity | -67.85% |
|---|---|
| Return on Assets | -40.90% |
| Return on Invested Capital | -43.80% |
Valuation & Multiples
| P/E Ratio | -21.42 |
|---|---|
| PEG | -10.61 |
| Price to Sales | - |
| Price to Book Ratio | 0.7 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.92 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.4 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-2.04
Average shareholder expectationRevenue Estimate
$1.77 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-2.35
Average shareholder expectationRevenue Estimate
$22.70 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Revolution Medicines Inc
883 employees
CEO: Mark Goldsmith Revolution Medicines, Inc. is a biopharmaceutical company in the clinical development phase, concentrating on creating innovative, precisely targeted therapies for cancers driven by RAS pathway dysregulation. The firm's drug development ...